The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Chugai Pharma
Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).
 
Fumikata Hara
Research Funding - Chugai Pharma (Inst); Eisai (Inst)
 
Hirofumi Mukai
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Nippon Kayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Shozo Ohsumi
No Relationships to Disclose
 
Daisuke Yotsumoto
No Relationships to Disclose
 
Tsutomu Takashima
Honoraria - Chugai Pharma; Eisai; Taiho Pharmaceutical
 
Yasuo Hozumi
Consulting or Advisory Role - Kowa
 
Takanori Watanabe
No Relationships to Disclose
 
Tsuyoshi Saito
No Relationships to Disclose
 
Ken-ichi Watanabe
No Relationships to Disclose
 
Junji Tsurutani
No Relationships to Disclose
 
Tatsuya Toyama
Research Funding - Daiichi Sankyo (Inst); Novartis (Inst); Takeda (Inst)
 
Hiromitsu Akabane
No Relationships to Disclose
 
Reiki Nishimura
No Relationships to Disclose
 
Naruto Taira
Research Funding - AstraZeneca (Inst)
 
Yukari Uemura
No Relationships to Disclose
 
Yasuo Ohashi
Stock and Other Ownership Interests - Statcom
Honoraria - Sanofi
Consulting or Advisory Role - Chugai Pharma; Eisai; Shionogi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Takeda; Yakult Honsha